Navelbine

Uterine Cervical Neoplasms, Monotherapy, Metastatic Breast Cancer + 4 more
Treatment
4 FDA approvals
20 Active Studies for Navelbine

What is Navelbine

VinorelbineThe Generic name of this drug
Treatment SummaryVinorelbine is a chemotherapy drug used to treat breast cancer and non-small cell lung cancer (NSCLC). It was approved by the FDA in the 1990s specifically for NSCLC. Vinorelbine belongs to a group of drugs known as vinca alkaloids, which have been found to improve survival rates in patients with advanced NSCLC. However, treatment with vinorelbine can cause serious side effects. A study was done that showed that genetic mutations can affect how quickly the body clears vinorelbine, with some patients clearing the drug up to 4.3 times faster than others
Vinorelbineis the brand name
Navelbine Overview & Background
Brand Name
Generic Name
First FDA Approval
How many FDA approvals?
Vinorelbine
Vinorelbine
2003
22

Approved as Treatment by the FDA

Vinorelbine, otherwise called Vinorelbine, is approved by the FDA for 4 uses which include Metastatic Non-Small Cell Lung Cancer and Carcinoma, Non-Small-Cell Lung .
Metastatic Non-Small Cell Lung Cancer
Used to treat Metastatic Non-Small Cell Lung Cancer in combination with Cisplatin
Carcinoma, Non-Small-Cell Lung
Used to treat Locally Advanced Non-Small Cell Lung Cancer in combination with Cisplatin
Previously Untreated
Used to treat Previously Untreated in combination with Cisplatin
Malignant Neoplasms
Used to treat Metastatic Non-Small Cell Lung Cancer in combination with Cisplatin

Effectiveness

How Navelbine Affects PatientsVinorelbine is a medication used to fight tumors. It belongs to a group of drugs called vinca-alkaloids, which stop cancer cells from dividing by preventing them from forming the structures needed for cell division.
How Navelbine works in the bodyVinorelbine tartrate is a special type of vinca alkaloid that works to fight cancer. It does this by inhibiting the process of cell division, by attaching to the microtubule proteins in the cell. This prevents cells from dividing and reproducing, resulting in cell death. Vinorelbine also works to activate certain tumor suppressor genes, like p53, and deactivate certain cancer-promoting proteins. It also affects metabolism, respiration, and other essential cell functions. All of these effects together lead to the death of cancerous cells.

When to interrupt dosage

The dosage of Navelbine is contingent upon the diagnosed issue, including Monotherapy, Soft Tissue Sarcoma and Malignant Neoplasms. The quantity of dosage is further dependent upon the administration approach (e.g. Solution - Intravenous or Solution) elucidated in the accompanying table.
Condition
Dosage
Administration
Uterine Cervical Neoplasms
, 10.0 mg/mL, 50.0 mg/mL
, Intravenous, Injection, solution, Injection, solution - Intravenous, Injection, solution, concentrate, Injection, solution, concentrate - Intravenous, Injection, Injection - Intravenous, Solution, Solution - Intravenous
Monotherapy
, 10.0 mg/mL, 50.0 mg/mL
, Intravenous, Injection, solution, Injection, solution - Intravenous, Injection, solution, concentrate, Injection, solution, concentrate - Intravenous, Injection, Injection - Intravenous, Solution, Solution - Intravenous
Carcinoma, Non-Small-Cell Lung
, 10.0 mg/mL, 50.0 mg/mL
, Intravenous, Injection, solution, Injection, solution - Intravenous, Injection, solution, concentrate, Injection, solution, concentrate - Intravenous, Injection, Injection - Intravenous, Solution, Solution - Intravenous
Malignant Neoplasms
, 10.0 mg/mL, 50.0 mg/mL
, Intravenous, Injection, solution, Injection, solution - Intravenous, Injection, solution, concentrate, Injection, solution, concentrate - Intravenous, Injection, Injection - Intravenous, Solution, Solution - Intravenous
Soft Tissue Sarcoma
, 10.0 mg/mL, 50.0 mg/mL
, Intravenous, Injection, solution, Injection, solution - Intravenous, Injection, solution, concentrate, Injection, solution, concentrate - Intravenous, Injection, Injection - Intravenous, Solution, Solution - Intravenous
Previously Untreated
, 10.0 mg/mL, 50.0 mg/mL
, Intravenous, Injection, solution, Injection, solution - Intravenous, Injection, solution, concentrate, Injection, solution, concentrate - Intravenous, Injection, Injection - Intravenous, Solution, Solution - Intravenous
Metastatic Breast Cancer
, 10.0 mg/mL, 50.0 mg/mL
, Intravenous, Injection, solution, Injection, solution - Intravenous, Injection, solution, concentrate, Injection, solution, concentrate - Intravenous, Injection, Injection - Intravenous, Solution, Solution - Intravenous

Warnings

There are 20 known major drug interactions with Navelbine.
Common Navelbine Drug Interactions
Drug Name
Risk Level
Description
2-Methoxyethanol
Major
The risk or severity of adverse effects can be increased when Vinorelbine is combined with 2-Methoxyethanol.
9-(N-methyl-L-isoleucine)-cyclosporin A
Major
The risk or severity of adverse effects can be increased when Vinorelbine is combined with 9-(N-methyl-L-isoleucine)-cyclosporin A.
Abetimus
Major
The risk or severity of adverse effects can be increased when Vinorelbine is combined with Abetimus.
Acteoside
Major
The risk or severity of adverse effects can be increased when Vinorelbine is combined with Acteoside.
Aldosterone
Major
The risk or severity of adverse effects can be increased when Vinorelbine is combined with Aldosterone.
Navelbine Toxicity & Overdose RiskVinorelbine has been linked to a variety of potential side effects, including decreased white blood cell count, infections, anemia, tingling or numbness in the extremities, hair loss, difficulty breathing, nausea, constipation, vomiting, diarrhea, fatigue, abdominal pain, chest pain, jaw pain, muscle aches, joint aches, headaches, difficulty swallowing, skin rash, bleeding in the bladder, and abnormal production of a hormone. It may also affect the chromosomes in the body. These side effects vary in severity and some may be life-threatening.
image of a doctor in a lab doing drug, clinical research

Navelbine Novel Uses: Which Conditions Have a Clinical Trial Featuring Navelbine?

155 active studies are being conducted to assess the potential of Navelbine as a Monotherapy, Previously Untreated and Soft Tissue Sarcoma Treatment.
Condition
Clinical Trials
Trial Phases
Metastatic Breast Cancer
1 Actively Recruiting
Phase 1, Phase 2
Carcinoma, Non-Small-Cell Lung
13 Actively Recruiting
Phase 3, Phase 2, Early Phase 1, Not Applicable
Monotherapy
1 Actively Recruiting
Phase 1, Phase 2
Malignant Neoplasms
3 Actively Recruiting
Phase 1, Phase 2
Uterine Cervical Neoplasms
0 Actively Recruiting
Previously Untreated
0 Actively Recruiting
Soft Tissue Sarcoma
51 Actively Recruiting
Phase 2, Not Applicable, Phase 1, Phase 4, Early Phase 1, Phase 3

Navelbine Reviews: What are patients saying about Navelbine?

5Patient Review
10/23/2013
Navelbine for Breast Cancer that has Spread to Another Part of the Body
Navelbine was fantastic for my bone and soft tissue cancer in my neck. I had weekly treatments for six months with very minimal side effects-- just some leg fatigue at the six month mark. I stopped taking it because of the leg pain, but if my current treatment stops working, I can go back on Navelbine. Right now, my cancer is stable.
5Patient Review
7/20/2013
Navelbine for Breast Cancer that has Spread to Another Part of the Body
Navelbine was really the first treatment that helped me. I had bone mets from breast cancer and the pain was unbearable. But after beginning this medication, I felt so much better almost immediately!
5Patient Review
7/8/2009
Navelbine for Cancer of the Uterus
My mom has been battling lung cancer for over 10 years and we've tried a lot of different treatments. This is one of the last options, but it's working really well for her. She doesn't have many side effects and is able to live a normal life including going shopping and exercising twice a week!
5Patient Review
1/22/2009
Navelbine for Breast Cancer that has Spread to Another Part of the Body
I've been taking this medication for almost four years, and it's been working great! The only downside is the side effects, but they're manageable.
4.7Patient Review
6/24/2013
Navelbine for Breast Cancer that has Spread to Another Part of the Body
I'm currently on my fifth cycle of this medication, and the biggest complaint I have is the fatigue. The nausea is easily dealt with a zofran/ativan combo, but the fatigue has been tough to manage. However, it's worth it because this medication has kept my cancer from growing (it's stable).
4.7Patient Review
6/1/2017
Navelbine for Breast Cancer that has Spread to Another Part of the Body
I've now completed five out of six cycles and the results have been great so far. The main side effects I've experienced are constipation, hair thinning, and fatigue. All things considered, it's been relatively easy to tolerate.
4.3Patient Review
8/14/2008
Navelbine for Non-Small Cell Lung Cancer
This treatment has been working well for my mother during her cancer battle. She doesn't experience any nausea, but her blood pressure can be all over the place. Additionally, she's lost hair and is very tired.
4.3Patient Review
6/26/2008
Navelbine for Breast Cancer that has Spread to Another Part of the Body
I had a really bad headache, stomach pain, and feeling weak. I think my blood pressure was low because I felt confused, too.
4Patient Review
4/15/2009
Navelbine for Non-Small Cell Lung Cancer
I take this once a month with few side effects and have been in remission since I started.
3Patient Review
3/17/2011
Navelbine for Non-Small Cell Lung Cancer
My husband has been taking this medication for two months with little to no relief from his symptoms. He was diagnosed in October 2009 and we're hoping for the best, but so far this treatment hasn't helped much.
3Patient Review
1/14/2009
Navelbine for Breast Cancer that has Spread to Another Part of the Body
I was really struggling until I stopped taking this.
3Patient Review
2/22/2008
Navelbine for Non-Small Cell Lung Cancer
1.7Patient Review
3/25/2012
Navelbine for Non-Small Cell Lung Cancer
This medication caused a significant decrease in my white blood cells, and I also experienced a lot of bone pain and wheezing.
1.3Patient Review
1/17/2010
Navelbine for Breast Cancer that has Spread to Another Part of the Body
After developing a severe chest infection, I started to experience extreme gastritis and weakness. The metastases were also extremely severe.
1Patient Review
10/29/2009
Navelbine for Non-Small Cell Lung Cancer
I'm looking for information about

Patient Q&A Section about navelbine

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

How often is Navelbine given?

"The dosage of NAVELBINE should be 30 mg/m2 given as an IV either as an injection or an infusion over 6-10 minutes. This should be done once a week in combination with cisplatin 120 mg/m2 given on days 1 and 29. This process should be repeated every 6 weeks."

Answered by AI

How effective is Navelbine?

"A phase 2 clinical trial that is studying the effectiveness of navelbine (vinorelbine) as a single-agent first-line treatment is showing a partial response rate of 24%, a stable disease rate of 55% with 21% of patients experiencing disease progression during treatment. This means that out of 100 patients treated with this drug, 24% saw their cancer shrink, 55% saw their cancer stay the same, and 21% saw their cancer grow."

Answered by AI

Does Navelbine cause neuropathy?

"The most common adverse reactions to NAVELBINE when used as a single agent include low white blood cell count, low neutrophil count, low hemoglobin, increased AST, nausea, vomiting, constipation, fatigue, reaction at the injection site, and peripheral neuropathy."

Answered by AI

What is Navelbine used to treat?

"Vinorelbine is a chemotherapy drug used for the treatment of breast cancer. Navelbine is the brand name for this drug."

Answered by AI

Clinical Trials for Navelbine

Image of University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center in Cleveland, United States.

Pulmonary Rehabilitation for Lung Cancer

18+
All Sexes
Cleveland, OH
This study is for people who have previously been diagnosed with advanced stage non-small cell lung cancer (NSCLC). Many people with advanced stage NSCLC have trouble breathing and feel tired. People may be eligible for this study if they have advanced stage NSCLC and feel short of breath some of the time. NSCLC survivors may also experience things like fatigue and a lower quality of life. Pulmonary rehabilitation is a type of supportive treatment that may improve these symptoms. This study has two parts. The first part is a randomized trial where half of the participants receive eight weeks of pulmonary rehabilitation. The other half of participants do not do pulmonary rehabilitation and instead receive the treatment that their doctors would normally recommend. The purpose of this part of the research study is to understand if pulmonary rehabilitation can help people with advanced stage NSCLC have better functioning and less shortness of breath. The other part of the research study is an interview study. The purpose of doing interviews is to understand any challenges or obstacles that people with advanced stage NSCLC may have regarding pulmonary rehabilitation, as well as oncology care providers have with their participants going to pulmonary rehabilitation.
Phase 2
Recruiting
University Hospitals Seidman Cancer Center, Case Comprehensive Cancer CenterMelinda Hsu, MD, MS
Have you considered Navelbine clinical trials? We made a collection of clinical trials featuring Navelbine, we think they might fit your search criteria.Go to Trials
Have you considered Navelbine clinical trials? We made a collection of clinical trials featuring Navelbine, we think they might fit your search criteria.Go to Trials
Image of BRCR Medical Center, Inc. in Plantation, United States.

Virus Therapy and Chemotherapy for Lung Cancer

18+
All Sexes
Plantation, FL
This Phase 2, open-label, randomized study in non-small-cell lung cancer (NSCLC) is designed to evaluate the efficacy and safety of an intravenously delivered oncolytic vaccinia virus, Olvi-Vec, followed by platinum-doublet chemotherapy + Physician's Choice of Immune Checkpoint Inhibitor (ICI) vs. docetaxel for patients with advanced or metastatic NSCLC who have shown first disease progression (i.e., progressive disease not yet confirmed by further scan after initial scan showing progression) while on front-line treatment or maintenance ICI therapy after front-line treatment with platinum-doublet chemotherapy + ICI as standard of care.
Phase 2
Recruiting
BRCR Medical Center, Inc. (+15 Sites)Newsoara Biopharma Co., Ltd.
Image of Lombardi Comprehensive Cancer Center, Georgetown University in Washington, United States.

Chemo-Immunotherapy for Lung Cancer

18+
All Sexes
Washington, United States
The goal of this clinical trial is to learn about neoadjuvant cemiplimab with histology-specific chemotherapy followed by resection and adjuvant cemiplimab in stage 3 non-small cell lung cancer (NSCLC) with contralateral mediastinal or ipsilateral supraclavicular lymph node (N3) involvement.. The main question it aims to answer is whether patients with stage 3 NSCLC with involvement of lymph nodes can undergo surgery to remove the cancer after receiving treatment with chemotherapy + immunotherapy. Participants will receive FDA-approved chemotherapy called platinum-doublet chemotherapy together with an immunotherapy drug targeting the immune marker PD-1 called cemiplimab. Patients will receive a 3 drug combination for 4 total treatments given every 3 weeks before surgery. After surgery, patients will have the option to undergo radiation therapy if it is recommended by their treatment team. After this, they will receive cemiplimab every 3 weeks for one year.
Phase 2
Recruiting
Lombardi Comprehensive Cancer Center, Georgetown University (+3 Sites)Joshua Reuss, MDRegeneron Pharmaceuticals
Have you considered Navelbine clinical trials? We made a collection of clinical trials featuring Navelbine, we think they might fit your search criteria.Go to Trials
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security